About N-myc proto-oncogene protein
N-myc proto-oncogene protein (MYCN) is a protein
from Homo sapiens identified by UniProt accession
P04198, 464 residues long.
MolForge cross-references it against 0 known binders and
503 disease associations.
Target properties
| Protein name | N-myc proto-oncogene protein |
| UniProt accession | P04198 |
| Gene | MYCN |
| Organism | Homo sapiens |
| Length | 464 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (503)
Diseases linked to this target (Open Targets).
- Feingold syndrome type 1 · score 0.82
- neurodegenerative disease · score 0.53
- genetic disorder · score 0.52
- megalencephaly-polydactyly syndrome · score 0.52
- basal cell carcinoma · score 0.47
- lymphocyte count · score 0.42
- body height · score 0.40
- appendicular lean mass · score 0.39
- melanoma · score 0.38
- skin basal cell carcinoma · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04198-F1 | alphafold | PREDICTED | 60.15 | — |
Amino-acid sequence (464 residues)
MPSCSTSTMP GMICKNPDLE FDSLQPCFYP DEDDFYFGGP DSTPPGEDIW KKFELLPTPP LSPSRGFAEH SSEPPSWVTE MLLENELWGS PAEEDAFGLG GLGGLTPNPV ILQDCMWSGF SAREKLERAV SEKLQHGRGP PTAGSTAQSP GAGAASPAGR GHGGAAGAGR AGAALPAELA HPAAECVDPA VVFPFPVNKR EPAPVPAAPA SAPAAGPAVA SGAGIAAPAG APGVAPPRPG GRQTSGGDHK ALSTSGEDTL SDSDDEDDEE EDEEEEIDVV TVEKRRSSSN TKAVTTFTIT VRPKNAALGP GRAQSSELIL KRCLPIHQQH NYAAPSPYVE SEDAPPQKKI KSEASPRPLK SVIPPKAKSL SPRNSDSEDS ERRRNHNILE RQRRNDLRSS FLTLRDHVPE LVKNEKAAKV VILKKATEYV HSLQAEEHQL LLEKEKLQAR QQQLLKKIEH ARTC
Explore N-myc proto-oncogene protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets